Inhaled insulin developer Dance Biopharm announced that it has signed an agreement with DarioHealth to integrate its smart soft mist inhaler into DarioHealth’s digital platform. The integration, which will allow patients using the SMI to get usage data in real time through a mobile app, is expected to be completed in time for upcoming clinical trials and would be modified for a marketed device if a Dance inhaler gets regulatory approval.
Dance recently presented positive results from a Phase 2 trial of its Dance 501 inhaled insulin for the treatment of Type 2 diabetes. The DarioHealth platforms have specific features for diabetes management and include a glucose monitoring system and optional blood pressure monitoring for patients and the capability for integration into healthcare provider systems.
Dance Biopharm CEO Anne Whitaker commented, “We are excited to partner with DarioHealth in empowering patients to take charge of their chronic illness. This platform is well established in the digital therapeutics space and has demonstrated positive behavior change in patients with chronic diseases through its user-centered approach. We share a similar goal of adapting our platforms to chronic diseases beyond diabetes. Dance Biopharm is exploring opportunities to pair the smart inhaler with gentle mist biologic formulations beyond insulin. Our initial focus is on rare and severe diseases in the endocrinology, respiratory, and cardiovascular space, where our platform and expertise present a unique opportunity to achieve better treatment efficiency.”
DarioHealth CEO Erez Raphael said, “Diabetes is a complex chronic condition that evolves over time, making real-time, streamed patient data essential to care. Through this strategic alliance, we are excited to expand the potential for our patient-centered, diabetes care and management solutions by integrating the smart inhaler, optimized to deliver a gentle mist formulation of insulin through the lungs, into our digital therapeutics platform, which includes blood glucose and blood pressure monitoring systems. Our goal is to place control of diabetes management directly into the hands of our users and, pending completion of clinical trials and regulatory approval, we believe that this alliance will help advance that critical objective.”
Read the Dance Biopharm and DarioHealth press release.
